Featured Post from Aston University

Manuka honey could help to clear deadly drug-resistant lung infection – research

Sep 8, 2022

4 min

Dr Jonathan A. G. Cox



• Scientists develop a potential nebulisation treatment using manuka honey to clear a drug resistant lung infection that can be fatal in cystic fibrosis patients

• Aston University researchers combined the antibiotic amikacin with manuka honey as a novel treatment for Mycobacterium abscessus

• Using the manuka honey combination resulted in an eight-fold reduction in the dosage of the antibiotic


A potential new treatment combining natural manuka honey with a widely used drug has been developed by scientists at Aston University to treat a potentially lethal lung infection and greatly reduce side effects of one of the current drugs used for its treatment.


The findings, which are published in the journal Microbiology, show that the scientists in the Mycobacterial Research Group in the College of Health and Life Sciences at Aston University were able to combine manuka honey and the drug amikacin in a lab-based nebulisation formulation to treat the harmful bacterial lung infection Mycobacterium abscessus.


Manuka honey is long known to have wide ranging medicinal properties, but more recently has been identified for its broad spectrum antimicrobial activity. Now scientists have found that manuka honey has the potential to kill a number of drug resistant bacterial infections such as Mycobacterium abscessus – which usually affects patients with cystic fibrosis (CF) or bronchiectasis.


According to the Cystic Fibrosis Trust, CF is a genetic condition affecting around 10,800 people - one in every 2,500 babies born in the UK -and there are more than 100,000 people with the condition worldwide. The NHS defines bronchiectasis as a long-term condition where the airways of the lungs become widened, leading to a build-up of excess mucus that can make the lungs more vulnerable to infection..

In the study, the researchers used samples of the bacteria Mycobacterium abscessus taken from 16 infected CF patients. They then tested the antibiotic amikacin, combined with manuka honey, to discover what dosage was required to kill the bacteria.


As part of the study the team used a lab-based lung model and nebuliser - a device that produces a fine spray of liquid often used for inhaling a medicinal drug. By nebulising manuka honey and amikacin together, it was found they could improve bacterial clearance, even when using lower doses of amikacin, which would result in less life-changing side-effects to the patient.


In the UK, of the 10,800 people living with CF, Mycobacterium abscessus infects 13% of all patients with the condition. This new approach is advantageous not only because it has the potential to kill off a highly drug resistant infection, but because of the reduced side effects, benefitting quality of life and greatly improving survival chances for infected CF patients.


Mycobacterium abscessus is a bacterial pathogen from the same family that causes tuberculosis, but this bug differs by causing serious lung infections in people (particularly children) with pre-existing lung conditions, such as CF and bronchiectasis, as well as causing skin and soft tissue infections. The bacteria is also highly drug resistant.


Currently, patients are given a cocktail of antibiotics, consisting of 12 months or more of antimicrobial chemotherapy and often doesn’t result in a cure. The dosage of amikacin usually used on a patient to kill the infection is 16 micrograms per millilitre. But the researchers found that the new combination using manuka honey, required a dosage of just 2 micrograms per millitre of amikacin - resulting in a one eighth reduction in the dosage of the drug.


Until now Mycobacterium abscessus has been virtually impossible to eradicate in people with cystic fibrosis. It can also be deadly if the patient requires a lung transplant because they are not eligible for surgery if the infection is present.


Commenting on their findings, lead author and PhD researcher Victoria Nolan said:


"So far treatment of Mycobacterium abscessus pulmonary infections can be problematic due to its drug resistant nature. The variety of antibiotics required to combat infection result in severe side effects.

"However, the use of this potential treatment combining amikacin and manuka honey shows great promise as an improved therapy for these terrible pulmonary infections.

“There is a need for better treatment outcomes and in the future we hope that this potential treatment can be tested further.”


Dr Jonathan Cox, senior lecturer in microbiology, Aston University said:


“By combining a totally natural ingredient such as manuka honey with amikacin, one of the most important yet toxic drugs used for treating Mycobacterium abscessus, we have found a way to potentially kill off these bacteria with eight times less drug than before. This has the potential to significantly reduce amikacin-associated hearing loss and greatly improve the quality of life of so many patients – particularly those with cystic fibrosis.

“I am delighted with the outcome of this research because it paves the way for future experiments and we hope that with funding we can move towards clinical trials that could result in a change in strategy for the treatment of this debilitating infection.”


Dr Peter Cotgreave, chief executive of the Microbiology Society said:


"The Microbiology Society is proud to support the scientific community as it explores innovative solutions to overcome the growing global challenge of antimicrobial resistance. This study demonstrates one of many ways in which microbiologists are pioneering new methods to tackle drug-resistant infections, by incorporating natural products, like manuka honey, into existing therapies."


For more information about the School of Biosciences, please visit our website.



Connect with:
Dr Jonathan A. G. Cox

Dr Jonathan A. G. Cox

Lecturer in Microbiology

Dr Cox's research interests surround the discovery of new antibiotics & identifying the mechanisms by which those antibiotics kill bacteria.

Health SciencesBiochemistryAntibioticsAntimicrobial ResistanceMicro-Organisms

You might also like...

Check out some other posts from Aston University

3 min

Aston University’s Professor Ian Maidment receives prestigious National Institute for Health and Care Research award

Professor Ian Maidment has received a National Institute for Health and Care Research (NIHR) Senior Investigator Award The award recognises his outstanding leadership contributions to the work of the NIHR and his excellent track record of securing NIHR funding Professor Maidment is the first academic at Aston University to receive the honour. Professor Ian Maidment at Aston Pharmacy School has received a prestigious Senior Investigator Award from the National Institute for Health and Care Research (NIHR). The NIHR gives the award to researchers in recognition of outstanding leadership contributions to the work of the NIHR and an excellent track record of securing NIHR funding. As a senior investigator, Professor Maidment will act as an ambassador for NIHR, and help to guide strategy and tackle challenges in the health and social care landscape. He will join the NIHR College of around 200 senior investigators. Professor Maidment is the first academic at Aston University to receive the award and one of few pharmacists in the UK to receive such an award. Professor Maidment joined Aston University in 2012 as a senior lecturer, which marked his first step into academia after more than 20 years working in the NHS, both as a pharmacist and leading R&D. During his time in the NHS, he published 40 papers in peer-reviewed journals. These formed the basis of a PhD by previous publication, and Professor Maidment was the first person to obtain a PhD at Aston University by this route. He was promoted to reader in 2018 and a full chair in 2022. Professor Maidment specialises in the health care of older people and those with mental health conditions, and the use of medication to treat them. This includes projects investigating the long-standing and international healthcare priority of managing anti-psychotic weight gain. From this research project, guidance will be developed both for patients and practitioners. His research with older people has identified the need to focus on reducing medication burden and investigating the link between some medications and dementia. He also studies how to best use the expertise of community pharmacy to improve outcomes, for example in COVID vaccination and more recently how to make independent prescribing by community pharmacy work better; the importance of this issue was identified by UK Prime Minister Keir Starmer. The award also recognises Professor Maidment’s strong links with the NIHR and critically his continued role in supporting its work. This includes mentoring other researchers, leadership and contributing to the development of the NIHR. Professor Maidment said: “Optimising medication in the real world is a key research priority; about half of all people struggle with adherence to medication. Much of my research has been focused on bringing the patient voice to key research questions. If we can fully understand the patient and family carer view, then we can start to get the medication right.” Professor Anthony Hilton, Aston University pro-vice-chancellor and executive dean of the College of Health and Life Sciences, said: “Professor Ian Maidment’s NIHR Senior Investigator Award is a well-deserved recognition of his exceptional research in medication safety and the care of older adults and people with severe mental illness, such as schizophrenia. His work has not only advanced academic understanding but has also shaped real-world healthcare practices, improving outcomes for patients. “This achievement reflects his dedication, expertise and commitment to impactful research and his outstanding leadership contributions to the work of the NIHR. At Aston University, we are delighted to celebrate Ian’s success and the significant contribution he continues to make to the field.”

4 min

Aston University study reveals the illusion of ‘dazzle’ paint on World War I battleships

The Zealandia in wartime dazzle paint. Image: Australian National Maritime Museum on The Commons Geometric ‘dazzle’ camouflage was used on ships in WWI to confuse enemy onlookers as to the direction and speed of the ship Timothy Meese and Samantha Strong reanalysed historic data from 1919 and found that the ‘horizon effect’ is more effective for confusion When viewing a ship at distance, it often appears to be travelling along the horizon, regardless of its actual direction of travel – this is the ‘horizon effect’. A new analysis of 105-year-old data on the effectiveness of ‘dazzle’ camouflage on battleships in World War I by Aston University researchers Professor Tim Meese and Dr Samantha Strong has found that while dazzle had some effect, the ‘horizon effect’ had far more influence when it came to confusing the enemy. During World War I, navies experimented with painting ships with ‘dazzle’ camouflage – geometric shapes and stripes – in an attempt to confuse U-boat captains as to the speed and direction of travel of the ships and make them harder to attack. The separate ‘horizon effect’ is when a person looks at a ship in the distance, and it appears to be travelling along the horizon, regardless of its actual direction of travel. Ships travelling at an angle of up to 25° relative to the horizon appear to be travelling directly along it. Even with those at a greater angle to the horizon, onlookers significantly underestimate the angle. Despite widespread use of dazzle camouflage, it was not until 1919 that a proper, quantitative study was carried out, by MIT naval architecture and marine engineering student Leo Blodgett for his degree thesis. He painted model ships in dazzle patterns and placed them in a mechanical test theatre with a periscope, like those used by U-boat captains, to measure how much onlookers’ estimations of the ships’ direction of travel deviated from their actual direction of travel. Professor Meese and Dr Strong realised that while the data collected by Blodgett was useful, his methods of experimental design fell short of modern standards. He’d found that dazzle camouflage worked, but the Aston University team suspected that dazzle alone was not responsible for the results seen, cleaned the data and designed new analysis to better understand what it really shows. Dr Strong, a senior lecturer at Aston University’s School of Optometry, said: “It's necessary to have a control condition to draw firm conclusions, and Blodgett's report of his own control was too vague to be useful. We ran our own version of the experiment using photographs from his thesis and compared the results across the original dazzle camouflage versions and versions with the camouflage edited out. Our experiment worked well. Both types of ships produced the horizon effect, but the dazzle imposed an additional twist.” If the errors made by the onlookers in the perceived direction of travel of the ship were entirely due to the ‘twist’ on perspective caused by dazzle paintwork, the bow, or front, of the ship, would always be seen to twist away from its true direction. However, Professor Meese and Dr Strong instead showed that when the true direction was pointing away from the observer, the bow was often perceived to twist towards the observer instead. Their detailed analysis showed a small effect of twist from the dazzle camouflage but a much larger one from the horizon effect. Sometimes these effects were in competition, sometimes in harmony. Professor Meese, a professor of vision science at the School of Optometry, said: “We knew already about the twist and horizon effects from contemporary computer-based work with colleagues at Abertay University. The remarkable finding here is that these same two effects, in similar proportions, are clearly evident in participants familiar with the art of camouflage deception, including a lieutenant in a European navy. This adds considerable credibility to our earlier conclusions by showing that the horizon effect – which has nothing to do with dazzle – was not overcome by those best placed to know better. “This is a clear case where visual perception is more powerful than knowledge. In fact, back in the dazzle days, the horizon effect was not identified at all, and Blodgett's measurements of perceptual bias were attributed entirely to the camouflage, deceiving the deceivers.” Professor Meese and Dr Strong say that more work is required to fully understand how dazzle might have increased perceptual uncertainty of direction and speed but also the geometry behind torpedo-aiming tactics that might have supported some countermeasures. Visit https://doi.org/10.1177/20416695241312316 to read the full paper in i-Perception.

1 min

Lab grown meat could be on sale in UK within two years - but what is lab-grown meat?

Meat, dairy and sugar grown in a lab could be on sale in the UK for human consumption for the first time within two years, sooner than expected. The Food Standards Agency (FSA) is looking at how it can speed up the approval process for lab-grown foods. Such products are grown from cells in small chemical plants. UK firms have led the way in the field scientifically but feel they have been held back by the current regulations. Aston University has been working on cultivated meat - find out more about what lab-made meat is  made of and how it is created in the podcast Breaking Down Barriers on Spotify   https://open.spotify.com/episode/7bFy1gr2LJCwiRLPAT9Hml For further details contact Nicola Jones, Press and Communications Manager, on (+44) 7825 342091 or email: n.jones6@aston.ac.uk

View all posts
Powered by